Author

Gregory L. Szeto

h-index 3 View on Semantic Scholar

We have 2 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor

Summary Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate designed to deliver the microtubule-disrupting agent monomethyl auristatin E (MMAE) to tumor cells. Using preclinical models of urothelial cancer (UC), we expand the understanding of the multifaceted mechanism of action for enfortumab vedotin tha...

Devra J. Olson, Bernard A. Liu, Patrick Younan et al. · Cell Reports Medicine · 0 citations

Open access Sep 2026

20 PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415)

Abstract Background Renal cell carcinoma (RCC) is characterized by an immunogenic tumor microenvironment and frequent activation of angiogenic pathways. Therefore, combining immune checkpoint blockade with VEGF pathway inhibition is a rational therapeutic approach. PF‑08634404 is an investigational anti–PD‑1 and anti‑V...

T. Choueiri, S. Pal, T. Powles et al. · The Oncologist · 0 citations